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Introduction {#s1}
============

Prior to the availability of insulin, people who developed diabetes before the age of 30 died within an average of 1.4 years of disease onset [@pone.0113635-Joslin1]. The commercial production of insulin in the 1920 s saw a dramatic decrease in mortality for Type 1 diabetes mellitus patients. Whilst the secular downward trend in mortality among the general population over the twentieth century is well known [@pone.0113635-Kesteloot1], it has not been as well documented in the type 1 diabetes population. One small study in Bucharest reported the decline in mortality over 6 decades [@pone.0113635-Ioacara1], whilst other studies only examine this trend in people with type 1 diabetes over the past decade [@pone.0113635-Ioacara1]--[@pone.0113635-Nishimura1].

The introduction of blood glucose self-monitoring and the increased awareness of the importance of controlling blood glucose to reduce the onset and progression of diabetic complications following the publication of the Diabetes Complications and Complications Trial (DCCT) [@pone.0113635-DCCT1] have led to an intensification of treatment. This has translated into improved life expectancy for patients with type 1 diabetes [@pone.0113635-Ioacara1], [@pone.0113635-Miller1], however it is unclear whether mortality for Type 1 diabetes patients relative to the general population has reduced over time.

Studies have quantified the increased relative risk (RR) of mortality for people with Type 1 diabetes compared with the general population, but there has been no systematic review to estimate pooled measures of RR or to explore the degree to which these vary across regions and over time. A recent large scale study [@pone.0113635-The1] involving individual participant data from 97 prospective studies was unable to separate people with Type 1 and Type 2 diabetes, and so could only provide overall estimates of relative mortality. Type 1 diabetes is typically diagnosed at young ages, and patients are susceptible over a longer period of time [@pone.0113635-Daneman1] to diabetic complications (e.g. renal disease, neuropathy, macrovascular disease); all of which may elevate mortality.

The purpose of this study was to undertake a systematic review of RR of mortality among Type 1 diabetes patients compared to the general population and to conduct a meta-analysis of the findings. Sub-group meta-analyses and meta-regression were also conducted to explore the extent to which the heterogeneity between studies could be explained by temporal changes in the relative risk of mortality for type 1 diabetes patients relative to the general population.

Materials and Methods {#s2}
=====================

Data Sources and Searches {#s2a}
-------------------------

Our systematic review aimed to identify studies that compared mortality of Type 1 diabetes patients to the general population and that reported RRs of mortality or standardised mortality ratios (SMR).

We identified studies for inclusion using a systematic literature search of the electronic databases: MEDLINE, EMBASE, CINAHL, PubMed and Cochrane's systematic reviews. Other databases that were used: The Health Economic Evaluation Database (HEED); the Digital Theses Database; Google Scholar; the TUFTS CEA register; NHS Economic Evaluation Database and the Health Technology Assessment website. We used Google Scholar and Pubmed to conduct a citation search of identified studies and we also examined the citations list of reported articles to identify further potential studies.

Study Selection {#s2b}
---------------

Inclusion criteria included articles published before April 2012 in English in peer reviewed journals in which study subjects have Type 1 diabetes and the overall mortality (as opposed to complication specific studies) among Type 1 diabetes patients is compared to the general population. The review was limited to human studies. Review articles were excluded after references lists had been searched. Where multiple papers used the same cohort in estimating a RR of mortality, only the one that used the longest follow-up was included into the analysis. Studies generally explicitly identified Type 1 diabetes populations. However, we identified Type 1 diabetes populations if patients were diagnosed under 30 years of age and/or classified as insulin only if the study was not clear in its description of diabetes patients.

Data Extraction and Quality Assessment {#s2c}
--------------------------------------

The reported RR estimates and their standard errors were extracted from each study for the meta-analysis. Studies that did not report uncertainty around their RR estimate (through standard error or confidence intervals) were excluded from both the meta-analysis and meta-regression. Multiple observations from some studies [@pone.0113635-Asao1]--[@pone.0113635-Podar1] were only included if the estimates used different populations to estimate these observations.

We assessed the quality of studies by completing the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) checklist for cohort studies.

Two independent reviewers examined the abstracts and full texts of all articles to determine whether the inclusion criteria were fulfilled. The reviewers also independently extracted the data for the meta-analysis and meta-regression. A third reviewer was assigned to re-examine all full text articles to ensure all data extracted was correct and finalise any discrepancies between the first two reviewers.

Data Synthesis and Analysis {#s2d}
---------------------------

A meta-analysis was conducted for the RR of mortality for Type 1 diabetes mellitus patients, which pools the results gathered from multiple studies into an overall average effect size. We used the DerSimonian and Laird random effects model for the meta-analysis, which accounts for both the within study variation and expected between study heterogeneity and was conducted in Stata version 12.0 (Stata Corporation, College Station, TX, USA). Studies that measured multiple RRs for different population groups were used as separate observations. We conducted a trim-and-fill analysis to explore the potential of publication bias from our studies.

To explore the possible reasons for heterogeneity among studies numerous sub-group meta-analyses were conducted along with a multivariate meta-regression. Fixed-effects inverse variance meta-analyses were conducted to explore heterogeneity across the categorical groups of studies. Study characteristics extracted for sub-group analysis and meta-regression included:

i.  A binary variable comparing studies conducted in European countries to non-European countries

ii. A continuous variable for the year of the median study date in estimating the relative risk of mortality

iii. A binary variable for sex

iv. A continuous variable for the sample size of the study

v.  A binary variable comparing patients' age at diagnosis to be less than 18 years to patients older than 18 years.

The sub-group meta-analyses were conducted for:

i.  Sex

ii. Studies conducted in Europe, in non-European countries and in the United Kingdom

iii. Studies which used a dataset commencing before 1971, between 1971--80, between 1981--1990, and after 1990

iv. Studies including patients who were diagnosed before 18 years of age only and studies including patients who were diagnosed after 18 years of age

Results and Discussion {#s3}
======================

Literature search and study characteristics {#s3a}
-------------------------------------------

A flow chart of the literature search and its results are reported in [Figure 1](#pone-0113635-g001){ref-type="fig"}. Initially, the search identified 22,844 titles and abstracts from all databases. 145 studies were reviewed in full, of which 39 studies were initially included. However, some studies provided more than one RR estimate. Studies [@pone.0113635-Brown1], [@pone.0113635-Nystrom1], [@pone.0113635-Sartor1] and certain observations of studies [@pone.0113635-Morrish1] were excluded if they used the same database as other studies, with a shorter follow-up period. Only 2 studies were different between the first two reviewers, which the third reviewer finalised the discrepancies after discussing the issue between the reviewers.

![Flow chart of study selection process.](pone.0113635.g001){#pone-0113635-g001}

The meta-analysis and meta-regression used 88 observations from 26 different studies [@pone.0113635-Nishimura1], [@pone.0113635-Asao1], [@pone.0113635-Florkowski1], [@pone.0113635-McNally1], [@pone.0113635-Podar1], [@pone.0113635-Morrish1]--[@pone.0113635-Wibell1]. Only 1 study estimated RR using hazard ratios [@pone.0113635-SoedamahMuthu1] and all other studies used SMRs. Details of the studies used, summary statistics and meta-analysis results are shown in [Table 1](#pone-0113635-t001){ref-type="table"}. Studies were conducted in 20 different countries, and the number of patients ranged from 75 to 12,684 per study, with a median of 382 patients. Patient age ranged between 1--79 years, with the majority diagnosed before 18 years. Full search terms of the database MEDLINE and the STROBE checklist for all studies included in the analysis can be found in the electronic supplementary material (Table S1 & Table S2 in [File S1](#pone.0113635.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0113635.t001

###### List of studies used in meta-analysis, country of analysis, date of conducted studies, age at diagnosis, mean age patients, number of patients in the study, percentage of males in study, years of follow-up, mortality rates and measurement of risk of mortality.
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  Study                                                        Country       Study period   Age at diagnosis     n      Mortality Rates (95% CI)   Type of Study   Relative Risk Type    Sex
  -------------------------------------------------------- ---------------- -------------- ------------------ -------- -------------------------- --------------- -------------------- --------
  Alleman et al. 2009 [@pone.0113635-Botha1]                 Switzerland      1974--2006         35--54         104        3.80 (3.00--4.80)          Cohort              SMR            Male
  Alleman et al. 2009 [@pone.0113635-Botha1]                 Switzerland      1974--2006         35--54         174        5.40 (4.30--6.80)          Cohort              SMR           Female
  Asao et al. 2003 [@pone.0113635-Asao1]                       Finland        1965--1979          \<18          2817       3.20 (2.80--3.70)          Cohort              SMR            Male
  Asao et al. 2003 [@pone.0113635-Asao1]                       Finland        1965--1979          \<18          2309       5.20 (4.20--6.30)          Cohort              SMR           Female
  Asao et al. 2003 [@pone.0113635-Asao1]                        Japan         1965--1979          \<18          566        9.00 (6.80--11.70)         Cohort              SMR            Male
  Asao et al. 2003 [@pone.0113635-Asao1]                        Japan         1965--1979          \<18          842       18.50 (14.70--23.00)        Cohort              SMR           Female
  Barcelo et al. 2007 [@pone.0113635-Bruno1]                     Cuba         1965--1970          \<10          259        8.58 (6.18--12.28)         Cohort              SMR            Male
  Barcelo et al. 2007 [@pone.0113635-Bruno1]                     Cuba         1965--1970          \<10          245        8.82 (6.70--12.74)         Cohort              SMR           Female
  Barcelo et al. 2007 [@pone.0113635-Bruno1]                United States     1965--1970          \<10          449        3.42 (2.36--5.13)          Cohort              SMR            Male
  Barcelo et al. 2007 [@pone.0113635-Bruno1]                United States     1965--1970          \<10          438        3.78 (2.66--5.56)          Cohort              SMR           Female
  Botha et al. 1992 [@pone.0113635-ColladoMesa1]            UK and Ireland    1972--1981          \<2           179        2.30 (0.60--9.50)          Cohort              SMR            Male
  Botha et al. 1992 [@pone.0113635-ColladoMesa1]            UK and Ireland    1972--1981          \<2           131        9.90 (4.10--24.20)         Cohort              SMR           Female
  Bruno et al. 2009 [@pone.0113635-Feltbower1]                  Italy         1974--2000          \<30          688        1.71 (0.99--2.95)          Cohort              SMR            Male
  Bruno et al. 2009 [@pone.0113635-Feltbower1]                  Italy         1974--2000          \<30          522        2.86 (1.29--6.37)          Cohort              SMR           Female
  Collado-mesa et al. 1997 [@pone.0113635-Gnavi1]                Cuba         1965--1991          \<15          259        7.50 (5.30--10.30)         Cohort              SMR            Male
  Collado-mesa et al. 1997 [@pone.0113635-Gnavi1]                Cuba         1965--1991          \<15          245       10.00 (6.90--14.60)         Cohort              SMR           Female
  Feltbower et al. 2008 [@pone.0113635-Grauslund1]             England        1978--2004         15--29         568        5.80 (3.80--8.60)          Cohort              SMR            Male
  Feltbower et al. 2008 [@pone.0113635-Grauslund1]             England        1978--2004        \< = 14         1742       4.20 (3.20--5.50)          Cohort              SMR            Male
  Feltbower et al. 2008 [@pone.0113635-Grauslund1]             England        1978--2004         15--29         329        7.50 (3.40--14.30)         Cohort              SMR           Female
  Feltbower et al. 2008 [@pone.0113635-Grauslund1]             England        1978--2004        \< = 14         1607       4.10 (2.60--6.30)          Cohort              SMR           Female
  Florkowski et al. 2003 [@pone.0113635-Florkowski1]         New Zealand      1984--1999          \<30          206        3.00 (2.20--4.00)          Cohort              SMR            Male
  Florkowski et al. 2003 [@pone.0113635-Florkowski1]         New Zealand      1984--1999        \> = 30          NA        1.60 (1.30--1.90)          Cohort              SMR            Male
  Florkowski et al. 2003 [@pone.0113635-Florkowski1]         New Zealand      1984--1999          \<30          229        2.70 (1.90--3.90)          Cohort              SMR           Female
  Florkowski et al. 2003 [@pone.0113635-Florkowski1]         New Zealand      1984--1999        \> = 30          NA        1.70 (1.40--2.00)          Cohort              SMR           Female
  Gnavi et al. 2004 [@pone.0113635-Harjutsalo1]                 Italy         1991--1999        \> = 20          NA        1.98 (1.56--2.47)          Cohort              SMR            Male
  Gnavi et al. 2004 [@pone.0113635-Harjutsalo1]                 Italy         1991--1999        \> = 20          NA        3.36 (2.59--4.28)          Cohort              SMR           Female
  Grausland 2010 [@pone.0113635-Joner1]                        Denmark        1973--2006           NA            NA        3.20 (2.80--3.70)          Cohort              SMR            Male
  Grausland 2010 [@pone.0113635-Joner1]                        Denmark        1973--2006           NA            NA        3.50 (3.00--4.10)          Cohort              SMR           Female
  Harjutsalo et al. 2011 [@pone.0113635-Laing1]                Finland        1970--1999        \< = 14          NA        3.00 (2.70--3.40)          Cohort              SMR            Male
  Harjutsalo et al. 2011 [@pone.0113635-Laing1]                Finland        1970--1999         15--29        93,559      2.60 (2.04--2.80)          Cohort              SMR            Male
  Harjutsalo et al. 2011 [@pone.0113635-Laing1]                Finland        1970--1999        \< = 14          NA        5.50 (4.80--6.30)          Cohort              SMR           Female
  Harjutsalo et al. 2011 [@pone.0113635-Laing1]                Finland        1970--1999         15--29        56,345      3.70 (3.20--4.30)          Cohort              SMR           Female
  Joner & Patrick 1991 [@pone.0113635-Nystrom1]                 Norway        1973--1988        \< = 14        1,040       2.15 (1.20--3.55)          Cohort              SMR            Male
  Joner & Patrick 1991 [@pone.0113635-Nystrom1]                 Norway        1973--1988        \< = 14         874        1.86 (0.60--4.34)          Cohort              SMR           Female
  Laing et al. 1999 [@pone.0113635-Muggeo1]                 United Kingdom    1972--1997          \<30         12,684      2.70 (2.50--2.90)          Cohort              SMR            Male
  Laing et al. 1999 [@pone.0113635-Muggeo1]                 United Kingdom    1972--1997          \<30         11,047      4.00 (3.60--4.40)          Cohort              SMR           Female
  McNally et al. 1995 [@pone.0113635-McNally1]                 England        1940--1949          \<17          463        9.44 (4.91--18.14)         Cohort              SMR            Male
  McNally et al. 1995 [@pone.0113635-McNally1]                 England        1950--1959          \<17          463        6.12 (3.18--11.75)         Cohort              SMR            Male
  McNally et al. 1995 [@pone.0113635-McNally1]                 England        1960--1969          \<17          463        2.99 (1.34--6.65)          Cohort              SMR            Male
  McNally et al. 1995 [@pone.0113635-McNally1]                 England        1970--1979          \<17          463        2.30 (0.87--6.10)          Cohort              SMR            Male
  McNally et al. 1995 [@pone.0113635-McNally1]                 England        1980--1989          \<17          463        1.69 (0.24--11.96)         Cohort              SMR            Male
  McNally et al. 1995 [@pone.0113635-McNally1]                 England        1940--1949          \<17          382       10.55 (4.41--25.22)         Cohort              SMR           Female
  McNally et al. 1995 [@pone.0113635-McNally1]                 England        1950--1959          \<17          382        2.86 (0.71--11.41)         Cohort              SMR           Female
  McNally et al. 1995 [@pone.0113635-McNally1]                 England        1960--1969          \<17          382        5.91 (1.91--18.31)         Cohort              SMR           Female
  McNally et al. 1995 [@pone.0113635-McNally1]                 England        1970--1979          \<17          382        4.78 (1.82--12.60)         Cohort              SMR           Female
  McNally et al. 1995 [@pone.0113635-McNally1]                 England        1980--1989          \<17          382        4.05 (0.57--28.54)         Cohort              SMR           Female
  Morrish et al. 2001 [@pone.0113635-Barcelo1]                 Croatia        1975--1988           NA           222        3.46 (2.14--5.28)          Cohort              SMR            Male
  Morrish et al. 2001 [@pone.0113635-Barcelo1]                 Croatia        1975--1988           NA           180        3.36 (1.09--7.84)          Cohort              SMR           Female
  Morrish et al. 2001 [@pone.0113635-Barcelo1]                   Cuba         1975--1988           NA           258        6.85 (4.06--10.82)         Cohort              SMR            Male
  Morrish et al. 2001 [@pone.0113635-Barcelo1]                   Cuba         1975--1988           NA           257        7.90 (3.79--14.53)         Cohort              SMR           Female
  Morrish et al. 2001 [@pone.0113635-Barcelo1]                 Germany        1975--1988           NA           285        6.82 (4.95--9.15)          Cohort              SMR            Male
  Morrish et al. 2001 [@pone.0113635-Barcelo1]                 Germany        1975--1988           NA           275        6.55 (4.35--9.46)          Cohort              SMR           Female
  Morrish et al. 2001 [@pone.0113635-Barcelo1]                Hong Kong       1975--1988           NA           198        3.44 (1.65--6.32)          Cohort              SMR            Male
  Morrish et al. 2001 [@pone.0113635-Barcelo1]                Hong Kong       1975--1988           NA           224        6.37 (2.75--12.55)         Cohort              SMR           Female
  Morrish et al. 2001 [@pone.0113635-Barcelo1]                  Poland        1975--1988           NA           241        4.27 (3.17--5.62)          Cohort              SMR            Male
  Morrish et al. 2001 [@pone.0113635-Barcelo1]                  Poland        1975--1988           NA           245        7.00 (4.93--9.64)          Cohort              SMR           Female
  Morrish et al. 2001 [@pone.0113635-Barcelo1]               Switzerland      1975--1988           NA           278        3.92 (2.53--5.78)          Cohort              SMR            Male
  Morrish et al. 2001 [@pone.0113635-Barcelo1]               Switzerland      1975--1988           NA           256        7.42 (4.89--10.80)         Cohort              SMR           Female
  Morrish et al. 2001 [@pone.0113635-Barcelo1]              United Kingdom    1975--1988           NA           254        1.88 (1.13--2.94)          Cohort              SMR            Male
  Morrish et al. 2001 [@pone.0113635-Barcelo1]              United Kingdom    1975--1988           NA           243        3.38 (2.14--5.07)          Cohort              SMR           Female
  Muggeo et al. 1995 [@pone.0113635-Raymond1]                   Italy         1986--1991          \<18           95        2.70 (0.54--7.90)          Cohort              SMR            Male
  Muggeo et al. 1995 [@pone.0113635-Raymond1]                   Italy         1986--1991          \<18           75        5.08 (1.02--14.86)         Cohort              SMR           Female
  Nishimura et al. 2001 [@pone.0113635-Nishimura1]          United States     1965--1999          \<18          558        3.25 (2.55--3.98)            RCT               SMR            Male
  Nishimura et al. 2001 [@pone.0113635-Nishimura1]          United States     1965--1999          \<18          517        6.90 (5.51--8.46)            RCT               SMR           Female
  Podar et al. 2000 [@pone.0113635-Podar1]                     Estonia        1980--1995          \<30          269        4.41 (1.79--8.15)          Cohort              SMR            Male
  Podar et al. 2000 [@pone.0113635-Podar1]                     Estonia        1980--1995          \<30          249        4.86 (1.32--12.44)         Cohort              SMR           Female
  Podar et al. 2000 [@pone.0113635-Podar1]                     Finland        1980--1995          \<30         2,798       1.38 (0.84--2.13)          Cohort              SMR            Male
  Podar et al. 2000 [@pone.0113635-Podar1]                     Finland        1980--1995          \<30         2,358       2.26 (1.17--3.95)          Cohort              SMR           Female
  Podar et al. 2000 [@pone.0113635-Podar1]                    Lithuania       1983--1995          \<30          360        5.28 (2.73--9.22)          Cohort              SMR            Male
  Podar et al. 2000 [@pone.0113635-Podar1]                    Lithuania       1983--1995          \<30          338       12.56 (6.69--21.47)         Cohort              SMR           Female
  Raymond et al. 1995 [@pone.0113635-Riley1]                United Kingdom    1983--1992         Dec-94        2,482       1.49 (1.29--1.71)          Cohort              SMR            Male
  Raymond et al. 1995 [@pone.0113635-Riley1]                United Kingdom    1983--1992         Dec-94        2,088       1.77 (1.51--2.06)          Cohort              SMR           Female
  Riley et al. 1995 [@pone.0113635-Roberts1]                  Australia       1984--1993          \<30          263        3.20 (2.10--4.70)          Cohort              SMR            Male
  Riley et al. 1995 [@pone.0113635-Roberts1]                  Australia       1984--1993        \> = 30         186        1.40 (1.10--1.80)          Cohort              SMR            Male
  Riley et al. 1995 [@pone.0113635-Roberts1]                  Australia       1984--1993          \<30          217        7.30 (4.60--10.90)         Cohort              SMR           Female
  Riley et al. 1995 [@pone.0113635-Roberts1]                  Australia       1984--1993        \> = 30         169        2.20 (1.70--2.80)          Cohort              SMR           Female
  Roberts et al. 2004 [@pone.0113635-Sartor2]               United Kingdom    1968--1996          \<30         2,603       6.50 (4.40--9.00)          Cohort              SMR            Male
  Roberts et al. 2004 [@pone.0113635-Sartor2]               United Kingdom    1968--1996          \<30         2,389      12.80 (8.50--17.90)         Cohort              SMR           Female
  Sartor & Dahlquist 1995 [@pone.0113635-Skrivarhaug1]          Sweden        1977--1990          \<15         2,653       2.62 (1.72--4.00)          Cohort              SMR            Male
  Sartor & Dahlquist 1995 [@pone.0113635-Skrivarhaug1]          Sweden        1977--1990          \<15         2,341       3.84 (2.32--6.35)          Cohort              SMR           Female
  Skrivarhaug et al. 2006 [@pone.0113635-SoedamahMuthu1]        Norway        1973--2002          \<15         1,034       3.90 (3.10--4.90)          Cohort              SMR            Male
  Skrivarhaug et al. 2006 [@pone.0113635-SoedamahMuthu1]        Norway        1973--2002          \<15          872        4.00 (2.70--5.60)          Cohort              SMR           Female
  Soedamah-Muthu et al. 2006 [@pone.0113635-Swerdlow1]      United Kingdom    1992--1999        \< = 35        4,216       3.30 (2.70--4.00)          Cohort               HR            Male
  Soedamah-Muthu et al. 2006 [@pone.0113635-Swerdlow1]      United Kingdom    1992--1999        \< = 35        3,497       4.50 (3.50--5.60)          Cohort               HR           Female
  Swerdlow & Jones 1995 [@pone.0113635-Waernbaum1]          United Kingdom    1966--1992           NA          2,907       1.58 (1.50--1.66)          Cohort              SMR            Male
  Swerdlow & Jones 1995 [@pone.0113635-Waernbaum1]          United Kingdom    1966--1992           NA          2,874       2.31 (2.20--2.43)          Cohort              SMR           Female
  Waernbaum et al. 2006 [@pone.0113635-Wibell1]                 Sweden        1983--1999         15--34          NA        1.90 (1.50--2.40)          Cohort              SMR            Male
  Waernbaum et al. 2006 [@pone.0113635-Wibell1]                 Sweden        1983--1999         15--34          NA        1.60 (1.00--2.60)          Cohort              SMR           Female
  Wibell et al. 2001 [@pone.0113635-Smolina1]                   Sweden        1983--1992         15--34          NA        2.10 (1.30--3.10)          Cohort              SMR            Male
  Wibell et al. 2001 [@pone.0113635-Smolina1]                   Sweden        1983--1999         15--34          NA        1.50 (0.70--3.60)          Cohort              SMR           Female

Overall meta-analysis {#s3b}
---------------------

Results of the overall meta-analysis of 88 observations are shown in [Table 2](#pone-0113635-t002){ref-type="table"}, and a meta-analysis forest plot is depicted in [Figure 2](#pone-0113635-g002){ref-type="fig"}, stratified by a studies commencement date. Overall RR of mortality was estimated at 3.82 (95% CI 3.41, 4.29) for Type 1 diabetes mellitus patients compared to the general population. The I-squared value was estimated at 96.0%, indicating the high degree of heterogeneity across studies.

![Random effects meta-analysis by median study date (\< = 1970, 1971--1980, 1981--1990, \>1990).\
Horizontal bars and circles widths denote 95% CIs, and box sizes indicate relative weight in the analysis.](pone.0113635.g002){#pone-0113635-g002}

10.1371/journal.pone.0113635.t002

###### Meta-analysis results by different categories, showing the number observations used, the pooled estimate and 95% confidence intervals and I^2^ estimate for heterogeneity.

![](pone.0113635.t002){#pone-0113635-t002-2}

                                                           No. of studies   Pooled Estimate (95% CI)   I^2^ estimate
  ------------------------------------------------------- ---------------- -------------------------- ---------------
  All studies                                                    88            3.82 (3.41--4.29)           96.0%
  Studies commenced before 1970                                  10            5.80 (4.20--8.01)           69.5%
  Studies commenced between 1971--1980                           12            5.06 (3.44--7.45)           98.8%
  Studies commenced between 1981--1990                           50            3.59 (3.15--4.09)           93.1%
  Studies commenced after 1990                                   16            3.11 (2.47--3.91)           92.7%
  Studies with patients age at diagnosisbefore 18 years          41            4.93 (4.13--5.88)           90.8%
  Studies with patients age at diagnosisafter 18 years           8             2.41 (1.75--3.32)           94.7%
  Male                                                           44            3.25 (2.82--3.73)           95.3%
  Female                                                         44            4.54 (3.79--5.45)           95.8%
  United Kingdom studies                                         28            3.78 (3.13--4.57)           96.4%
  European studies                                               66            3.56 (3.16--4.00)           95.2%
  Non-European studies                                           22            4.63 (3.28--6.55)           97.0%

Subgroup analyses and meta-regression analysis to explore cross-study heterogeneity {#s3c}
-----------------------------------------------------------------------------------

All sub-group meta-analyses results are also shown in [Table 2](#pone-0113635-t002){ref-type="table"}. Fixed-effects inverse variance meta-analysis for all sub-groups found strong evidence of heterogeneity within sub-groups, and heterogeneity between sub-groups (p\<0.01). When conducting separate meta-analyses for men and women, RRs of death were 3.25 (95% CI 2.82, 3.73) and 4.54 (95% CI 3.79, 5.45), respectively. I-squared estimates of 95.3% (men) and 95.8% (women) showed similar heterogeneity as the overall meta-analysis results which suggest that heterogeneity between studies is not explained by gender differences. Similar results were shown for studies conducted in Europe and in the United Kingdom, with RR of mortality of 3.56 (95% 3.16, 4.00) and 3.78 (95% CI 3.13, 4.57), respectively. When stratified by the median study date, observations that used data prior to 1971 had a much higher estimated RR (5.80 (95% CI 4.20, 8.01)) than studies that used data after 1990 (3.11 (95% CI 2.47, 3.92)) with a clear temporal improvement in relative mortality over time. A large amount of heterogeneity can be explained from observations that used data prior to 1971, with an I-squared estimated at 69.5%, compared to 92.7% for studies after 1990.

Further investigation of the possible sources of between-study heterogeneity was performed through multivariate meta-regression analyses and reported in [Table 3](#pone-0113635-t003){ref-type="table"}. 24 studies and 76 observations were included into the primary meta-regression. We decided a linear temporal trend was a better fit than non-linear trends, based on adjusted R-squared values. The assumed linear temporal trend captured by the standardized median date of study was significant, suggesting an improving trend in relative mortality over time for studies whose median date was after 1982. By way of interpretation for every year increase in the year of the data used after 1982, the average RR of mortality decreased by 2%. Similarly, males had a lower RR of mortality on average by 30% than females. Studies conducted in Europe and the numbers of patients in studies were found to have an insignificant effect on the average RR of mortality in the meta-regression. When we included a binary variable to determine whether age at diagnosis was at childhood (\<18 years) in a separate meta-regression, it reduced our analysis to 20 studies and 56 observations shown in [Table 3](#pone-0113635-t003){ref-type="table"}. The newly introduced variable was found to have an insignificant effect. However, the adjusted R-squared estimates which explain the proportion of between-study variance improved from 21.8% to 25.74%, respectively.

10.1371/journal.pone.0113635.t003

###### Meta-regression results, determining the factors that account for the heterogeneity between different studies' relative risk of mortality estimates.

![](pone.0113635.t003){#pone-0113635-t003-3}

  24 studies, 74 observations                                         20 studies, 56 observations                                                                                                                   
  ------------------------------------------------------------------ ----------------------------- -------- ------ ------ ------------------------------------------------------------------ ------ -------- ------ ------
  Intercept                                                                      5.09               \<0.01   3.81   6.80                              Intercept                               6.05   \<0.01   4.45   8.21
  Median date of study[\*](#nt101){ref-type="table-fn"}                          0.98               \<0.01   0.97   0.99        Median date of study[\*](#nt101){ref-type="table-fn"}         0.98    0.03    0.97   0.99
  Sex (Male = 1)                                                                 0.70                0.01    0.54   0.90                            Sex (Male = 1)                            0.68    0.01    0.50   0.91
  Region (Europe[\*\*](#nt102){ref-type="table-fn"} = 1)                         0.80                0.13    0.60   1.07        Region (Europe[\*\*](#nt102){ref-type="table-fn"} = 1)        0.88    0.43    0.63   1.22
  Number of patients in study[\*\*\*](#nt103){ref-type="table-fn"}               0.99                0.34    0.99   1.00   Number of patients in study[\*\*\*](#nt103){ref-type="table-fn"}   0.99    0.35    0.99   1.00
                                                                                                                                        Age at diagnosis (\>18 years old = 1)                 0.66    0.13    0.38   1.13

\*Median date of study standardized by deducting the median date of studies of 1982.

\*\*66 observations conducted in Europe.

\*\*\*Number of patients in study standardized by deducting the mean number of patients of 1163.

The trim-and-fill analysis plot is reported in Figure S2 in [File S1](#pone.0113635.s001){ref-type="supplementary-material"}. No trimming of data has been performed, suggesting there is no evidence of publication bias.

Discussion {#s4}
==========

This study represents the first meta-analysis of the RRs of mortality for Type 1 diabetes patients compared to the general population. Although the meta-analysis showed on average over three-fold RR in mortality compared to the general population, there is a clear reduction in the risk of mortality when examining populations over time. Our sub-group analyses showed studies examining databases prior to 1971 had almost double the RR of mortality relative to the general population when compared to studies using databases after 1990. Whilst the general population's mortality has reduced during this period, it is clear that for type 1 diabetes patients, their mortality has been declining at an even faster rate than the general population.

To put this into perspective, a recent study estimated SMR in the months following an acute myocardial infarction to be four times greater which is similar to the overall relative mortality in our analysis across all studies [@pone.0113635-Smolina1]. As we have demonstrated above there is a significant decline in relative mortality. The pooled standardised mortality of studies initiated since 1990 suggests around a three-fold all-cause mortality risk. While this suggests significant improvements in relative survival of people with Type 1 diabetes, they are still at a greater mortality risk than people with Type 2 diabetes [@pone.0113635-Seshasai1], or long-term survivors of a myocardial infarction [@pone.0113635-Smolina1].

Our results also place in context two large studies estimating relative mortality of people with Type 1 diabetes based on registries in Denmark [@pone.0113635-Jorgensen1] and Scotland [@pone.0113635-Livingstone1]. While Jorgensen et al. [@pone.0113635-Jorgensen1] reported improvements in mortality rates in type 1 diabetes patients over the study period between 2002 and 2011, the relative risks of 2.58 (95% CI 2.23, 2.98) for men and 2.71 (95% CI 2.18, 3.38) reported in the Scottish study based on data collected between 2005 and 2007 [@pone.0113635-Livingstone1] are not significantly different from our estimates of all studies initiated since 1980.

While we have observed secular improvement in relative mortality for people with type 1 diabetes for over 50 years, the largest relative improvements occurred prior to 1980. However, it is important to continue to monitor the relative mortality of people with type 1 diabetes, particularly in light of published results from the DCCT [@pone.0113635-DCCT1] which indicate metabolic memory and legacy effects from intensive blood glucose control on complications of diabetes [@pone.0113635-Murray1], [@pone.0113635-RanjitUnnikrishnan1] which may translate into further improvements in mortality in coming years.

As expected there was a large amount of between-study heterogeneity. Differences between the composition of Type 1 diabetes cohorts in the study and the associated background population with which to estimate RR of mortality from along with studies being conducted at different time periods leads one to expect a certain level of heterogeneity between studies. We conducted a number of sub-group meta-analyses (European studies, non-European studies, stratification by commencement date of studies and sex) and still found high levels of heterogeneity, as represented by the large I-squared values in [Table 2](#pone-0113635-t002){ref-type="table"}. A random-effects meta-regression was conducted to combine the results of studies to account for the variation. The meta-regression shows a negative linear trend, with a coefficient of 0.98 (95% CI 0.97--0.99) suggesting decreasing relative mortality over time. The only other significant factor that explained the variation between studies was by sex as women were estimated to have a higher RR of mortality when compared to men, 4.54 (95% CI 3.79, 5.45) and 3.25 (95% CI 2.82, 3.73) respectively. This is indicative of the improving level of treatments for patients with Type 1 diabetes. However, there were still unobserved factors which attributed to heterogeneity after conducting a meta-regression and sub-group meta-analyses. Differences in the duration of studies and in the baseline characteristics of the type 1 diabetes patients, the background mortality of the general population to which the RR are calculated and the inconsistent reporting of patient characteristics across studies meant the influence of other confounders (diabetes-specific complications, duration of diabetes, median age of diagnosis, body weight, smoking, type of treatment regimen, HbA1c levels, etc.) that potentially could be associated with heterogeneity surrounding RR in mortality of Type 1 diabetes patients could not be assessed. Previous studies examining SMR's in a meta-analysis framework also reported high levels of between-study heterogeneity [@pone.0113635-Jess1], [@pone.0113635-Yurkovich1].

There was a considerable range of estimated RR of mortality, with the lowest estimated at 1.38 (95% CI 0.84--2.13) by a study in Finland [@pone.0113635-Podar1] and the highest RR of mortality estimated at 18.5 (95% CI 14.7--23.0) in Japan [@pone.0113635-Asao1]. Whilst this meta-analysis shows considerable heterogeneity in RR of mortality between different developed countries, there is a lack of information reported in less developed countries, and studies reporting mortality values were often based on a small number of cases [@pone.0113635-Soltesz1]. Further research needs to be conducted in order to determine the RR of mortality in developed countries compared to developing countries.

Conclusions {#s5}
===========

In conclusion, this study has estimated people with type 1 diabetes have an elevated risk of mortality when compared to the general population, although the gap between the two populations have been decreasing. However, the sub-group meta-analyses suggests that the largest reductions in relative mortality have been achieved prior to 1980, although improvements in treatments following the DCCT imply metabolic memory and legacy effects of intensive glucose control along with statin treatment and blood pressure control could potentially reduce relative mortality further in the future.
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###### 

**Tables S1 and S2 and Figures S1 and S2.** Table S1. Summary of terms used in the Medline search strategy. Table S2. STROBE checklist for cohort studies. Figure S1. Cumulative meta-analysis by median study date (\< = 1970, 1971--1980, 1981--1990,\>1990). Horizontal bars and circles widths denote 95% CIs, and box sizes indicate relative weight in the analysis. Figure S2. Trim-and-fill analysis of the included estimates. No trimming of data was performed, suggesting no evidence of publication bias.
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